Elanco executive takes Neurizon board observer seat

Neurizon has appointed Justine Conway, global head of business development at US animal-health group Elanco (NYSE: ELAN), as board observer, further tightening the companies’ partnership. She will join all board and committee meetings without voting rights, bringing long-running transaction and strategy experience from roles in Sydney, London and New York.

Her arrival follows Neurizon’s exclusive global licence for monepantel, the active ingredient in NUZ-001, which gives the biotech access to extensive safety datasets and established manufacturing know-how. Neurizon says this will strengthen regulatory submissions, support late-stage planning and help prepare NUZ-001 for entry into the HEALEY ALS Platform Trial this quarter.

Elanco, which generated $4.44 billion in revenue last year, has continued to build its innovation portfolio, reporting $461 million of newer-product sales in 2024, making it a commercially steady partner. Neurizon says Ms Conway’s presence will help steer the company’s expansion as it targets global commercialisation of NUZ-001, its lead ALS programme.